Scholars Central

EditorialPublished 28 May 2023

Kidney Cancer Overview

Authors: John Andrew

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Every year, more than 65,000 Americans receive a kidney cancer diagnosis, and about 13,000 people pass away from the condition. Kidney cancer is made up of several different cancer kinds, each of which has a unique histology, clinical course, and response to treatment, as well as being brought on by a separate gene. Kidney cancer is now understood to be a metabolic illness as a result of research into the thirteen genes that are known to cause kidney cancer. New areas of strong interest in the investigation of the underlying genetic basis of kidney cancer have been made possible by recent discoveries of chromatin remodeling/histone modifying genes, such as PBRM1 and SETD2. Ipilumumab, a CTLA4 inhibitor, and other novel immunotherapy strategies have opened up intriguing new avenues for clinical studies. The foundation for the creation of efficient treatments for this condition will hopefully be laid by a variety of fresh drugs that target VEGF receptor signaling, the mTOR pathway, and HIF2.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Oncology: Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Oncology: Case Reports
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “John Andrew”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels